Effectiveness of Drug Therapy in Abortion on Medical Indications in Hospital Conditions

Zhivko Zhekov; Svetlana  Radeva; Emil Kovachev

doi:10.3889/oamjms.2023.11794

Authors

Zhivko Zhekov Department of Obstetrics and Gynecology, Medical University of Varna, Varna, Bulgaria https://orcid.org/0009-0009-1272-7403
Svetlana Radeva Department of Health Care, Medical University of Varna, Varna, Bulgaria
Emil Kovachev Department of Obstetrics and Gynecology, Medical University of Varna, Varna, Bulgaria

DOI:

https://doi.org/10.3889/oamjms.2023.11794

Keywords:

medical abortion, malformations, prenatal diagnosis, medical commission

Abstract

BACKGROUND: The model in the Specialized Hospital of Obstetrics and Gynecology in Varna is becoming more and more widespread. The medical abortion, as a means of choice for behavior in abortion on medical indications, in hospital conditions, after the opinion of the commission to a hospital institution with a profile of specialty gynecology, and in case of abortion on request in hospital or pre-hospital medical activity. In Europe, this model has been in place for 30 years, and clinical experience shows that complications and mortality are many times lower than with surgery.

MATERIALS AND METHODS: Conducted own survey for the period January 2021-July 2023 of 37 patients who went through a pregnancy termination committee on medical grounds.

RESULTS AND DISCUSSION: About 89.2% of cases have a positive opinion of the commission in the hospital structure. Patients with higher education had better outpatient follow-up (χ2 = 12,662, p = 0.002). The greatest effectiveness is the three-fold administration of a drug regimen between 6 and 12 h (χ2 = 74,000, p = 0.000) and the gestation period of 12–20 g.w. (χ2 = 38.858, p = 0.025), and single drug administration during pregnancy (8–13 g.w.) (χ2 = 30.537, p = 0.006) and effect up to the 6th h (χ2 = 8.133, p = 0.004).

CONCLUSION: The choice of a method of medical behavior is the result of a complex approach with regard to a number of factors related to pregnancy, general somatic status, and carried out diagnostic activities. An applied therapeutic approach reduces hospital costs, and the patient has a quick recovery period. Early and timely diagnosis and outpatient follow-up of patients in pre-hospital care are important informative values.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Baird DT. Medical abortion in the first trimester. Best Pract Res Clin Obstet Gynaecol. 2002;16(2):221-36. https://doi.org/10.1053/beog.2001.0272 PMid:12041964 DOI: https://doi.org/10.1053/beog.2001.0272

Bracken H, Ngoc NT, Schaff E, Coyaji K, Ambardekar S, Westheimer E, et al. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion. Obstet Gynecol. 2007;109(4):895- 901. https://doi.org/10.1097/01.AOG.0000259319.18958.76 PMid:17400851 DOI: https://doi.org/10.1097/01.AOG.0000259319.18958.76

Løkeland M, Bjørge T, Iversen OE, Akerkar R, Bjørge L. Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. Int J Epidemiol. 2017;46(2):643-51. https://doi.org/10.1093/ije/dyw270 PMid:28031316 DOI: https://doi.org/10.1093/ije/dyw270

Løkeland M, Iversen OE, Engeland A, Økland I, Bjørge L. Medical abortion with mifepristone and home administration of misoprostol up to 63 days’gestation. Acta Obstet Gynecol Scand. 2014;93(7):647-53. https://doi.org/10.1111/aogs.12398 PMid:24766569 DOI: https://doi.org/10.1111/aogs.12398

Mannisto J. “The Effects of Termination of Pregnancy on Future Reproduction”, Academic Dissertation to be Presented with the Assent of the Doctoral Training Committee of Health and Biosciences of the University of Oulu for Public Defence in Auditorium 4 of Oulu University Hospital; 2017.

Bebbington MW, Kent N, Lim K, Gagnon A, Delisle MF, Tessier F, et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol. 2002;187(4):853-7. https://doi.org/10.1067/mob.2002.127461 PMid:12388963 DOI: https://doi.org/10.1067/mob.2002.127461

Marinov D. Medicosocial and Economic Aspects of Medicated Abortion in Bulgaria. National Center for Public Health, Author of Dissertation for Acquisition of Educational and Scientific Degree “Doctor”, Sofia; 2020г.

Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur J Contracept Reprod Health Care. 2000;5(3):171-6. https://doi.org/10.1080/13625180008500394 PMid:11131781 DOI: https://doi.org/10.1080/13625180008500394

Auffret M, Bernard-Phalippon N, Dekemp J, Carlier P, Gervoise Boyer M, Vial T, et al. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol. 2016;207:188-92. https://doi.org/10.1016/j.ejogrb.2016.11.007 PMid:27865944 DOI: https://doi.org/10.1016/j.ejogrb.2016.11.007

Stoykov S. Medical abortion-HIT or SHIT? Med Info. 2013;2:1- 4. Available from: https://medinfo.bg/ymoaltak/magazines/1454/ article_pdf/316-1362917120-41bea140c0dcb29d313e480b71 fdb745.pdf

National Abortion Federation, Protocol for Early Abortion with Mifepristone and Misoprostol; 2016.

WHO. Safe abortion: Technical and Policy Guidance for Health Systems. 2nd ed. Geneva: World Health Organization; 2004.